Take­da com­mits to a $230M pack­age to seal block­buster neu­ro­log­i­cal R&D deal with Wave Life Sci­ences

Biotech gi­ant Take­da is en­ter­ing a mega-sized part­ner­ship with Wave Life Sci­ences, a Cam­bridge, Mass­a­chu­setts-based com­pa­ny, to work on a se­ries of pro­grams for neu­ro­log­i­cal dis­or­ders. The pact in­cludes a hefty up­front check and $2 bil­lion in po­ten­tial mile­stone mon­ey for Wave.

The part­ner­ship comes in two pieces. First, Wave $WVE will give Take­da the op­tion to co-de­vel­op and co-com­mer­cial­ize pro­grams in Hunt­ing­ton’s dis­ease, amy­otroph­ic lat­er­al scle­ro­sis (ALS), fron­totem­po­ral de­men­tia, and spin­ocere­bel­lar atax­ia type 3. Take­da will al­so have the right to li­cense sev­er­al pre­clin­i­cal pro­grams tar­get­ing CNS dis­or­ders, in­clud­ing Alzheimer’s and Parkin­son’s.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER